Vexev Pty Ltd

Vexev Pty Ltd is a healthcare technology company specializing in advanced vascular imaging solutions. Their flagship product, the VxWave, automates ultrasound imaging to enhance clinical decision-making in vascular access management. Vexev Pty Ltd, founded in 2018 in Sydney, Australia, focuses on developing innovative vascular imaging technologies. The company has raised a total of AUD 5.

289 mn in funding, with the latest Seed round completed in January 2022. The investment was led by NeoTribe Ventures and included support from Blackbird. John Carroll serves as CEO, and the founding team includes Eamonn Colley. The company has completed 2 deals to date, with its current valuation at AUD 28.

585 mn. Vexev specializes in advanced vascular imaging solutions, centered around its flagship product, the VxWave. This autonomous ultrasound system utilizes robotics, machine learning, and high-resolution ultrasound technology to facilitate precise vascular imaging. Designed for non-specialists, the VxWave addresses the complexities of vascular access management, particularly for dialysis patients.

Vexev aims to revolutionize vascular diagnostics and treatment, primarily targeting healthcare providers in the United States, including dialysis centers and healthcare institutions focused on improving patient outcomes. Vexev's revenue model is structured around B2B transactions with healthcare providers and clinical institutions. The company provides advanced vascular imaging solutions, including training and ongoing support for the VxWave system. Revenue is generated through direct sales to healthcare facilities and potential service contracts, and may also be supported by participation in clinical trials and research partnerships, aligning with the emphasis on proactive healthcare and enhanced patient care.

Following their AUD 5. 29 mn Seed funding raised in January 2022, Vexev plans to expand its team and accelerate the development of its robotic ultrasound technology. The company is exploring opportunities to introduce new products and expand into additional markets beyond the United States, although specific regions and timelines for these initiatives have not been disclosed.